Are there any to avoid
Methods In this retrospective cohort study, 125 474 adults with overweight or obesity newly initiated treatment with a dual-labeled GLP-1 RA (liraglutide, semaglutide, or tirzepatide) between January 1, 2018, and December 31, 2023, with a baseline body mass index of 27 or more, an available weight measurement within 60 days before initiation, and regular care in the year before initiation were identified using electronic health record data from a collective of US health care systems
Some suggest that gluten-free diets may be beneficial, but more research is needed
Retatrutide adds a third component glucagon receptor agonism which is one of the reasons it has drawn so much attention in metabolic and obesity-related research
Key Background Novo Nordisk, the makers of Ozempic, Wegovy, Saxenda and Victoza, list thyroid cancer as a potential side effect of each medicine and warn against use if a type of thyroid cancer called medullary thyroid carcinoma runs in the family
